ГЕНЕТИКО-БІОЛОГІЧНІ МАРКЕРИ ПРОГНОЗУ РАКУ ТОВСТОГО КИШКІВНИКА
Ключові слова:
колоректальний рак, прогноз, діагностика, молекулярні маркери.Анотація
На сьогоднішній день актуальним є питання індивідуалізації лікування онкологічних хворих, в основі якого лежить визначення молекулярно-біологічних особливостей ракової хвороби конкретного пацієнта. У статті розглядаються сучасні дані літератури щодо можливого прогностичного значення основних молекулярних маркерів прогресування колоректального раку у їх зв’язку з патогенезом захворювання.
Посилання
1. Акимов А.А. Апоптоз и лучевая терапия злокачественных новообразований / А.А. Акимов, С.Д. Иванов, К.П. Хансон // Вопросы онколо-гии.– 2003.– Т.49, №3. – С. 261-269.
2. Делекторская В.В. Молекулярно-биологические маркеры метастазирования и прогноза при раке толстой кишки: дис. док. мед. наук: спец. 14.00.14 „Онкология” / В.В. Делекторская. – Москва, 2007. – 240 c.
3. Имятинов Е.Н. Клинико-молекулярные аспекты колоректального рака: этиопатогенез, профилактика, индивидуализация лечения / Е.Н. Имятинов // Практическая онкология. – 2005. – Т.6, №2.– С. 65-70.
4. Пальцев М.А. Межклеточные взаимодействия / М.А. Пальцев, А.А. Иванов, С.Е. Северин. – М.: Медицина, 2003.– 288 с.
5. Черипко О.Н. Факторы, влияющие на частоту возникновения рецидивов рака прямой кишки / О.Н. Черипко // Онкология. – 2002. – Т.4, №3. – С. 206-208.
6. Analysis of the immunohistochemical expressions of p53, bcl-2 and Ki-67 in colorectal adenocarcinoma and their correlations with the prognostic factors / H.L. Menezes, M.J. Jucá, E.G. Gomes et al. // Arq. Gastroenterol. – 2010. – Vol.47, N.2. – P. 141-147.
7. Apoptotic index and bcl-2 expression as prognostic factors in colorectal carcinoma / R. Bendardaf, R. Ristamaki, H. Kujari et al. // Oncology. – 2003. – Vol.64, N.4. – P. 435-442.
8. Beta–catenin and E-cadherin tissue "content" as prognostic markers in left–side colorectal cancer / N.P. Martinez, D.T. Kanno, J.A. Pereira et al. // Cancer Biomark. – 2010. – Vol.8, N.3. – P. 129-350.
9. Boland C.R. Microsatellite instability in colorectal cancer / C.R. Boland, A. Goel // Gastroenterology. – 2010. – Vol.138, N.6. – P. 2073-2087.
10. Buda А. Е-cadherin and the cytoskeletal network in colorectal cancer development and metastasis / A. Buda, M. Pignatelli // Cell Commun Adhes. – 2011. – Vol.18, N.6. – P. 133-143.
11. Chromosome aberrations in solid tumors / D.G. Albertson, C. Collins, F. McCormick, J.W. Gray // Nat Genet. – 2003. – Vol.34, N.4. – P. 369-376.
12. Cluster analysis of claudin-1 and -4, E-cadherin, and β-catenin expression in colorectal cancers / T. Matsuoka, H. Mitomi, N. Fukui et al. // J Surg Oncol. – 2011. – Vol.103, N.7. – P. 674-686.
13. Contu P.C. Bcl-2 expression in rectal cancer / P.C. Contu, S.S. Contu, L.F. Moreira // Arq Gastroenterol. – 2006. – Vol.43, N.4. – P. 284-287.
14. COX-2 overexpression in pretreatment biopsies predicts response of rectal cancers to neoadjuvant radiochemotherapy / F.M. Smith, J.V. Reynolds, E.W. Kay et al. // Int. J. Radiat. Oncol. Biol. Phys. – 2006. – Vol.64, N.2. – P. 466-472.
15. Cyclooxygenase-2 expression in pretreatment biopsy as a predictor of tumor responses after preoperative chemoradiation in rectal cancer / B.S. Min, Y.J. Choi, H.R. Pyo et al. // Arch. Surg. – 2008. – Vol.143, N.11. – P. 1091-1097.
16. Des Guetz G. Does microsatellite instability predict the efficacy of adjuvant chemotherapy in colorectal cancer? A systematic review with meta-analysis / G. Des Guetz, O. Schischmanoff, P. Nicolas et al. // Eur J Cancer. – 2009. – Vol.45, N.10. – P. 1890-1896.
17. Disparate clinicopathological correlations of p53 and Bcl-2 in colorectal cancer / P.C. Papagiorgis, A.E. Zizi, S. Tseleni et al. // Mol Med Report. – 2012. – Vol.5, N.2. – P. 377-382
18. E-cadherin expression pattern in primary colorectal carcinomas and their metastases reflects disease outcome / A. Elzagheid, A. Ålgars, R. Bendardaf et al. // World J Gastroenterol. – 2006. – Vol.12, N.27. – P. 4304-4309.
19. Expression of p53 and Ki-67 as Prognostic Factors for Survival of Men with Colorectal Cancer / F. Lumachi, R. Orlando, F. Marino et al. // Anticancer Res. – 2012. – Vol.32, N.9. – P. 3965-3967.
20. Factors associated with anastomotic recurrence after total mesorectal excision in rectal cancer patients / Y.W. Kim, N.K. Kim, B.S. Min et al. // Journal of Surgical Oncology. – 2009. – Vol.99, N.1. – P. 58-64.
21. Factors influencing prognosis after neo–adjuvant chemoradiation therapy for rectal carcinoma / M. Moral, M.J. Fdez-Acenero, R. Cuberes, A. Sua- rez // Acta Chir. Belg. – 2009. – Vol.109, N.3. – P. 345-551.
22. Genetic markers predictive of response to induction chemoradiotherapy for locally advanced rectal cancers / M. Kudrimoti, E.Y. Lee, Y. Kang // J. Ky Med. Assoc. – 2007. – Vol.105, N.1. – P. 18-22.
23. High Ki67, Bax, and thymidylate synthase expression well correlates with response to chemoradiation therapy in locally advanced rectal cancers: Proposal of a logistic model for prediction / M. Kikuchi, T. Mikami, T. Sato et al. // Br. J. Cancer. – 2009. – Vol.101, N.1. – P. 116-123.
24. Huh J.W. Expression of p16, p53, and Ki-67 in colorectal adeno-carcinoma: a study of 356 surgically resected cases / J.W. Huh, J.H. Lee, H.R. Kim // Hepatogastroenterology. – 2010. – Vol.57, N.101. – P. 734-740.
25. Iacopetta B. Microsatellite instability in colorectal cancer / B. Iacopetta, F. Grieu, B. Amanuel // Asia–Pacific Journal of Clinical Oncology. – 2010. – Vol.6. – P. 260-269.
26. Is a proliferation index of cancer cells a reliable prognostic factor after hepatectomy in patients with colorectal liver metastases? / J.C. Weber, H. Nakano, P. Bachellier et al. // Am. J. Surg. – 2001. – Vol.182, N.1. – P. 81-88.
27. Jo W.S. Chemotherapeutic implications in microsatellite unstable colorectal cancer / W.S. Jo, J.M. Carethers // Cancer Biomark. – 2006. – Vol.2, N.1-2. – P. 51-60.
28. Kanthan R. Molecular events in primary and metastatic colorectal carcinoma: a review / R. Kanthan, J.L. Senger, S.C. Kanthan // Patholog Res Int. – 2012. – Vol. 2012. – P. 597-598.
29. KRAS mutation status is predictive of response to cetuximab therapy in colorectal cancer / A. Lièvre, J.B. Bachet, D. Le Corre et al. // Cancer Res. – 2006. – Vol.66, N.8. – P. 3992-3995.
30. Lin M.X. Expression and significance of Bmi-1 and Ki67 in colorectal carcinoma tissues / M.X. Lin, Z.F. Wen, Z.Y. Feng // Ai Zheng. – 2008. – Vol.27, N.12. – P. 1321-1326.
31. Loss of E-cadherin promotes the growth, invasion and drug resistance of co-lorectal cancer cells and is associated with liver metastasis / X. Chen, Y. Wang, H. Xia et al. // Mol Biol Rep. – 2012. – Vol.39, N.6. – P. 6707-6714.
32. Microsatellite instability does not predict the efficacy of chemotherapy in metastatic colorectal cancer. A systematic review and meta-analysis / G. Des Guetz, B. Uzzan, P. Nicolas et al. // Anticancer Res. – 2009. – Vol.29, N.5. – P. 1615-1620.
33. Molecular cytogenetics: genomic imbalances in colorectal cancer and their clinical impact / M. Grade, H. Becker, T. Liersch et al. // Cell Oncol. – 2006. – Vol.28, N.3.– P. 71-84.
34. Molecular pathways in colorectal cancer / S. Al–Sohaily, A. Biankin, R. Leong et al. // J Gastroenterol Hepatol. – 2012. – Vol.27, N.9. – P. 1423-1431.
35. Molecular responses of rectal cancer to preoperative chemoradiation /A. Debucquoy, L. Goethals, K. Geboes et al. // Radiother. Oncol. – 2006. – Vol.80, N.2. – P. 172-177.
36. p53 and p27 as predictors of clinical outcome for rectal-cancer patients receiving neoadjuvant therapy / L.C. Lin, H.H. Lee, W.S. Hwang et al. // Surg. Oncol. – 2006. – Vol.15, N.4. – P. 211-216.
37. Pathologic stage is most prognostic of disease-free survival in locally ad-vanced rectal cancer patients after preoperative chemoradiation / H.M. Quah, J. F. Chou, M. Gonen et al. // Cancer. – 2008. – Vol.113, N.1. – P. 57-64.
38. Potential role of bcl-2 and ki-67 expression and apoptosis in colorectal carcinoma: a clinicopathologic study / C.D. Scopa, A.C. Tsamandas, V. Zolota et al. // Dig Dis Sci. – 2003. – Vol.48, N.10. – P. 1990-1997.
39. Predictive Factors of the Response of Rectal Cancer to Neoadjuvant Radiochemotherapy / G. Spolverato, S. Pucciarelli, R. Bertorelle et al. // Cancers. – 2011. – Vol.3. – P. 2176-2194.
40. Predictive value of Ki67 and p53 in locally advanced rectal cancer: cor-relation with thymidylate synthase and histopathological tumor regression after neoadjuvant 5-FU-based chemoradiotherapy / C. Jakob, T. Liersch, W. Meyer et al. // World J. Gastroenterol. – 2008. – Vol.14, N.7. – P. 1060-1066.
41. Pritchard C.C. Colorectal cancer molecular biology moves into clinical practice / C.C. Pritchard, W.M. Grady // Gut. – 2011. – Vol.60, N.1. – P. 116-129.
42. Prognostic significance of epidermal growth factor receptor and vascular endothelial growth factor receptor in colorectaladenocarcinoma / J.Y. Kim, B.N. Bae, J.E. Kwon et al. // APMIS. – 2011. – Vol.119, N.7. – P. 449-459.
43. Prognostic significance of histological features and biological parameters in stage I (pT1 and pT2) colorectal adenocarcinoma / L. Losi, G. Ponti, C.D. Gregorio et al. // Pathol Res Pract. – 2006. – V.202, N.9. – P. 663-670.
44. Prognostic significance of the wnt signalling pathway molecules APC, beta-catenin and E-cadherin in colorectal cancer: a tissue microarray-based analysis / A. Lugli, I. Zlobec, P. Minoo et al. // Histopathology. – 2007. – Vol.50, N.4. – P. 453-464.
45. Prognostic values of radiation-induced p53 in adjacent normal mucosa and p21WAF1/CIP1 expression in rectal cancer patients / R. Yoshikawa, H. Yanagi, M. Kusunoki et al. // Int. J. Oncol. – 2002. – Vol.21, N.6. – P. 1223-1228.
46. Relationship and prognostic significance of SPARC and VEGF protein expression in colon cancer / J.F. Liang, H.K. Wang, H. Xiao et al. // J Exp Clin Cancer Res. – 2010. – Vol.29, N.1. – P. 71.
47. Scholzen T. The Ki-67 protein: From the known and the unknown /T. Scholzen, J. Gerdes // J. Cell. Physiol. – 2000. – Vol.182, N.3. – P. 311-322.
48. Siena S. Biomarkers predicting clinical outcome of epidermal growth factor receptor-targeted therapy in metastatic colorectal cancer / S. Siena,A. Sartore-Bianchi, F. Di Nicolantonio et al. // J Natl Cancer Inst. – 2009. – Vol.101, N.19. – P. 1308-1324.
49. Stage I colorectal carcinoma: VEGF immunohistochemical expression, microvessel density, and their correlation with clinical outcome / V. Barresi, C. Di Gregorio, L. Regiani-Bonetti et al. // Virchows Arch. – 2010. – Vol.457, N.1. – P. 11-19.
50. The molecular basis of chemoradiosensitivity in rectal cancer: implications for personalized therapies / M. Grade, H.A. Wolff, J. Gaedcke, B.M. Ghadi-mi // Langenbecks Arch Surg. – 2012. – Vol.397, N.4. – P. 543-555.
51. The survival effect of E-cadherin and catenins in colorectal carcinomas / A.I. Filiz, Z. Senol, I. Sucullu et al. // Colorectal Dis. – 2010. – Vol.12, N.12. – P. 1223-1230.
52. Thymidylate synthase expression, p53, bcl-2, Ki-67 and p27 in colorectal cancer: relationships with tumor recurrence and survival / G. Rosati, R. Chiac-chio, G. Reggiardo et al. // Tumour Biol. – 2004. – Vol.25, N.5-6. – P. 258-263.
53. Yamac D. Prognostic significance of COX-2 expression in colorectal carcinoma / D. Yamac, G. Celnkoglu, N. Akyurek // Ann. Onc. – 2002. – Vol.13. – P. 74.
2. Делекторская В.В. Молекулярно-биологические маркеры метастазирования и прогноза при раке толстой кишки: дис. док. мед. наук: спец. 14.00.14 „Онкология” / В.В. Делекторская. – Москва, 2007. – 240 c.
3. Имятинов Е.Н. Клинико-молекулярные аспекты колоректального рака: этиопатогенез, профилактика, индивидуализация лечения / Е.Н. Имятинов // Практическая онкология. – 2005. – Т.6, №2.– С. 65-70.
4. Пальцев М.А. Межклеточные взаимодействия / М.А. Пальцев, А.А. Иванов, С.Е. Северин. – М.: Медицина, 2003.– 288 с.
5. Черипко О.Н. Факторы, влияющие на частоту возникновения рецидивов рака прямой кишки / О.Н. Черипко // Онкология. – 2002. – Т.4, №3. – С. 206-208.
6. Analysis of the immunohistochemical expressions of p53, bcl-2 and Ki-67 in colorectal adenocarcinoma and their correlations with the prognostic factors / H.L. Menezes, M.J. Jucá, E.G. Gomes et al. // Arq. Gastroenterol. – 2010. – Vol.47, N.2. – P. 141-147.
7. Apoptotic index and bcl-2 expression as prognostic factors in colorectal carcinoma / R. Bendardaf, R. Ristamaki, H. Kujari et al. // Oncology. – 2003. – Vol.64, N.4. – P. 435-442.
8. Beta–catenin and E-cadherin tissue "content" as prognostic markers in left–side colorectal cancer / N.P. Martinez, D.T. Kanno, J.A. Pereira et al. // Cancer Biomark. – 2010. – Vol.8, N.3. – P. 129-350.
9. Boland C.R. Microsatellite instability in colorectal cancer / C.R. Boland, A. Goel // Gastroenterology. – 2010. – Vol.138, N.6. – P. 2073-2087.
10. Buda А. Е-cadherin and the cytoskeletal network in colorectal cancer development and metastasis / A. Buda, M. Pignatelli // Cell Commun Adhes. – 2011. – Vol.18, N.6. – P. 133-143.
11. Chromosome aberrations in solid tumors / D.G. Albertson, C. Collins, F. McCormick, J.W. Gray // Nat Genet. – 2003. – Vol.34, N.4. – P. 369-376.
12. Cluster analysis of claudin-1 and -4, E-cadherin, and β-catenin expression in colorectal cancers / T. Matsuoka, H. Mitomi, N. Fukui et al. // J Surg Oncol. – 2011. – Vol.103, N.7. – P. 674-686.
13. Contu P.C. Bcl-2 expression in rectal cancer / P.C. Contu, S.S. Contu, L.F. Moreira // Arq Gastroenterol. – 2006. – Vol.43, N.4. – P. 284-287.
14. COX-2 overexpression in pretreatment biopsies predicts response of rectal cancers to neoadjuvant radiochemotherapy / F.M. Smith, J.V. Reynolds, E.W. Kay et al. // Int. J. Radiat. Oncol. Biol. Phys. – 2006. – Vol.64, N.2. – P. 466-472.
15. Cyclooxygenase-2 expression in pretreatment biopsy as a predictor of tumor responses after preoperative chemoradiation in rectal cancer / B.S. Min, Y.J. Choi, H.R. Pyo et al. // Arch. Surg. – 2008. – Vol.143, N.11. – P. 1091-1097.
16. Des Guetz G. Does microsatellite instability predict the efficacy of adjuvant chemotherapy in colorectal cancer? A systematic review with meta-analysis / G. Des Guetz, O. Schischmanoff, P. Nicolas et al. // Eur J Cancer. – 2009. – Vol.45, N.10. – P. 1890-1896.
17. Disparate clinicopathological correlations of p53 and Bcl-2 in colorectal cancer / P.C. Papagiorgis, A.E. Zizi, S. Tseleni et al. // Mol Med Report. – 2012. – Vol.5, N.2. – P. 377-382
18. E-cadherin expression pattern in primary colorectal carcinomas and their metastases reflects disease outcome / A. Elzagheid, A. Ålgars, R. Bendardaf et al. // World J Gastroenterol. – 2006. – Vol.12, N.27. – P. 4304-4309.
19. Expression of p53 and Ki-67 as Prognostic Factors for Survival of Men with Colorectal Cancer / F. Lumachi, R. Orlando, F. Marino et al. // Anticancer Res. – 2012. – Vol.32, N.9. – P. 3965-3967.
20. Factors associated with anastomotic recurrence after total mesorectal excision in rectal cancer patients / Y.W. Kim, N.K. Kim, B.S. Min et al. // Journal of Surgical Oncology. – 2009. – Vol.99, N.1. – P. 58-64.
21. Factors influencing prognosis after neo–adjuvant chemoradiation therapy for rectal carcinoma / M. Moral, M.J. Fdez-Acenero, R. Cuberes, A. Sua- rez // Acta Chir. Belg. – 2009. – Vol.109, N.3. – P. 345-551.
22. Genetic markers predictive of response to induction chemoradiotherapy for locally advanced rectal cancers / M. Kudrimoti, E.Y. Lee, Y. Kang // J. Ky Med. Assoc. – 2007. – Vol.105, N.1. – P. 18-22.
23. High Ki67, Bax, and thymidylate synthase expression well correlates with response to chemoradiation therapy in locally advanced rectal cancers: Proposal of a logistic model for prediction / M. Kikuchi, T. Mikami, T. Sato et al. // Br. J. Cancer. – 2009. – Vol.101, N.1. – P. 116-123.
24. Huh J.W. Expression of p16, p53, and Ki-67 in colorectal adeno-carcinoma: a study of 356 surgically resected cases / J.W. Huh, J.H. Lee, H.R. Kim // Hepatogastroenterology. – 2010. – Vol.57, N.101. – P. 734-740.
25. Iacopetta B. Microsatellite instability in colorectal cancer / B. Iacopetta, F. Grieu, B. Amanuel // Asia–Pacific Journal of Clinical Oncology. – 2010. – Vol.6. – P. 260-269.
26. Is a proliferation index of cancer cells a reliable prognostic factor after hepatectomy in patients with colorectal liver metastases? / J.C. Weber, H. Nakano, P. Bachellier et al. // Am. J. Surg. – 2001. – Vol.182, N.1. – P. 81-88.
27. Jo W.S. Chemotherapeutic implications in microsatellite unstable colorectal cancer / W.S. Jo, J.M. Carethers // Cancer Biomark. – 2006. – Vol.2, N.1-2. – P. 51-60.
28. Kanthan R. Molecular events in primary and metastatic colorectal carcinoma: a review / R. Kanthan, J.L. Senger, S.C. Kanthan // Patholog Res Int. – 2012. – Vol. 2012. – P. 597-598.
29. KRAS mutation status is predictive of response to cetuximab therapy in colorectal cancer / A. Lièvre, J.B. Bachet, D. Le Corre et al. // Cancer Res. – 2006. – Vol.66, N.8. – P. 3992-3995.
30. Lin M.X. Expression and significance of Bmi-1 and Ki67 in colorectal carcinoma tissues / M.X. Lin, Z.F. Wen, Z.Y. Feng // Ai Zheng. – 2008. – Vol.27, N.12. – P. 1321-1326.
31. Loss of E-cadherin promotes the growth, invasion and drug resistance of co-lorectal cancer cells and is associated with liver metastasis / X. Chen, Y. Wang, H. Xia et al. // Mol Biol Rep. – 2012. – Vol.39, N.6. – P. 6707-6714.
32. Microsatellite instability does not predict the efficacy of chemotherapy in metastatic colorectal cancer. A systematic review and meta-analysis / G. Des Guetz, B. Uzzan, P. Nicolas et al. // Anticancer Res. – 2009. – Vol.29, N.5. – P. 1615-1620.
33. Molecular cytogenetics: genomic imbalances in colorectal cancer and their clinical impact / M. Grade, H. Becker, T. Liersch et al. // Cell Oncol. – 2006. – Vol.28, N.3.– P. 71-84.
34. Molecular pathways in colorectal cancer / S. Al–Sohaily, A. Biankin, R. Leong et al. // J Gastroenterol Hepatol. – 2012. – Vol.27, N.9. – P. 1423-1431.
35. Molecular responses of rectal cancer to preoperative chemoradiation /A. Debucquoy, L. Goethals, K. Geboes et al. // Radiother. Oncol. – 2006. – Vol.80, N.2. – P. 172-177.
36. p53 and p27 as predictors of clinical outcome for rectal-cancer patients receiving neoadjuvant therapy / L.C. Lin, H.H. Lee, W.S. Hwang et al. // Surg. Oncol. – 2006. – Vol.15, N.4. – P. 211-216.
37. Pathologic stage is most prognostic of disease-free survival in locally ad-vanced rectal cancer patients after preoperative chemoradiation / H.M. Quah, J. F. Chou, M. Gonen et al. // Cancer. – 2008. – Vol.113, N.1. – P. 57-64.
38. Potential role of bcl-2 and ki-67 expression and apoptosis in colorectal carcinoma: a clinicopathologic study / C.D. Scopa, A.C. Tsamandas, V. Zolota et al. // Dig Dis Sci. – 2003. – Vol.48, N.10. – P. 1990-1997.
39. Predictive Factors of the Response of Rectal Cancer to Neoadjuvant Radiochemotherapy / G. Spolverato, S. Pucciarelli, R. Bertorelle et al. // Cancers. – 2011. – Vol.3. – P. 2176-2194.
40. Predictive value of Ki67 and p53 in locally advanced rectal cancer: cor-relation with thymidylate synthase and histopathological tumor regression after neoadjuvant 5-FU-based chemoradiotherapy / C. Jakob, T. Liersch, W. Meyer et al. // World J. Gastroenterol. – 2008. – Vol.14, N.7. – P. 1060-1066.
41. Pritchard C.C. Colorectal cancer molecular biology moves into clinical practice / C.C. Pritchard, W.M. Grady // Gut. – 2011. – Vol.60, N.1. – P. 116-129.
42. Prognostic significance of epidermal growth factor receptor and vascular endothelial growth factor receptor in colorectaladenocarcinoma / J.Y. Kim, B.N. Bae, J.E. Kwon et al. // APMIS. – 2011. – Vol.119, N.7. – P. 449-459.
43. Prognostic significance of histological features and biological parameters in stage I (pT1 and pT2) colorectal adenocarcinoma / L. Losi, G. Ponti, C.D. Gregorio et al. // Pathol Res Pract. – 2006. – V.202, N.9. – P. 663-670.
44. Prognostic significance of the wnt signalling pathway molecules APC, beta-catenin and E-cadherin in colorectal cancer: a tissue microarray-based analysis / A. Lugli, I. Zlobec, P. Minoo et al. // Histopathology. – 2007. – Vol.50, N.4. – P. 453-464.
45. Prognostic values of radiation-induced p53 in adjacent normal mucosa and p21WAF1/CIP1 expression in rectal cancer patients / R. Yoshikawa, H. Yanagi, M. Kusunoki et al. // Int. J. Oncol. – 2002. – Vol.21, N.6. – P. 1223-1228.
46. Relationship and prognostic significance of SPARC and VEGF protein expression in colon cancer / J.F. Liang, H.K. Wang, H. Xiao et al. // J Exp Clin Cancer Res. – 2010. – Vol.29, N.1. – P. 71.
47. Scholzen T. The Ki-67 protein: From the known and the unknown /T. Scholzen, J. Gerdes // J. Cell. Physiol. – 2000. – Vol.182, N.3. – P. 311-322.
48. Siena S. Biomarkers predicting clinical outcome of epidermal growth factor receptor-targeted therapy in metastatic colorectal cancer / S. Siena,A. Sartore-Bianchi, F. Di Nicolantonio et al. // J Natl Cancer Inst. – 2009. – Vol.101, N.19. – P. 1308-1324.
49. Stage I colorectal carcinoma: VEGF immunohistochemical expression, microvessel density, and their correlation with clinical outcome / V. Barresi, C. Di Gregorio, L. Regiani-Bonetti et al. // Virchows Arch. – 2010. – Vol.457, N.1. – P. 11-19.
50. The molecular basis of chemoradiosensitivity in rectal cancer: implications for personalized therapies / M. Grade, H.A. Wolff, J. Gaedcke, B.M. Ghadi-mi // Langenbecks Arch Surg. – 2012. – Vol.397, N.4. – P. 543-555.
51. The survival effect of E-cadherin and catenins in colorectal carcinomas / A.I. Filiz, Z. Senol, I. Sucullu et al. // Colorectal Dis. – 2010. – Vol.12, N.12. – P. 1223-1230.
52. Thymidylate synthase expression, p53, bcl-2, Ki-67 and p27 in colorectal cancer: relationships with tumor recurrence and survival / G. Rosati, R. Chiac-chio, G. Reggiardo et al. // Tumour Biol. – 2004. – Vol.25, N.5-6. – P. 258-263.
53. Yamac D. Prognostic significance of COX-2 expression in colorectal carcinoma / D. Yamac, G. Celnkoglu, N. Akyurek // Ann. Onc. – 2002. – Vol.13. – P. 74.
##submission.downloads##
Опубліковано
2019-07-08
Як цитувати
Голотюк, В. В., Юркевич, Є. М., Голотюк, В. І., Семенів, П. М., Ткачук, Ю. Б., & Гончар, В. Г. (2019). ГЕНЕТИКО-БІОЛОГІЧНІ МАРКЕРИ ПРОГНОЗУ РАКУ ТОВСТОГО КИШКІВНИКА. ПРИКАРПАТСЬКИЙ ВІСНИК НТШ Пульс, (4(28), 45–53. вилучено із https://pvntsh.nung.edu.ua/index.php/pulse/article/view/804
Номер
Розділ
КЛІНІЧНА МЕДИЦИНА
